And more than investors are giving COEP the attention it deserves. COEP recently announced that research involving its SNAP-CAR technology was detailed in a peer-reviewed article in
Indeed, pioneering advances in the bio-pharmaceutical space do come with perks. One is industry attention, which they scored with the peer-reviewed publication. But another one, sometimes considered more valuable for biotech, is earning the attention of investors. After all, even with supporting data, the best of science can only get to the FDA approval finish line with cash behind it. Investors, institutional and retail, are instrumental in fueling those approval ambitions.
In that regard, Coeptis is worthy of the interest...and investment. Why? Because COEP isn't defined by a single headline or publication inclusion. Instead, the value inherent to COEP is better reflected as a sum of its parts consideration. And factoring the several initiatives that can enable them to grow bigger faster, current share prices appear to miss fair value. In other words, the Coeptis stock price may present a compelling value investment opportunity.
Peer Recognition Is Validating A Major Initiative
That's not an overly optimistic presumption, especially noting the particulars published in
Because research indicates and supports that these 'universal' receptor systems, where receptor specificity can be directed post-translationally through covalent attachment of a co-administered antibody, potentially allow for one population of T cells to target multiple tumor antigens. That enables the development of cell therapies for a wide range of cancers, including hematologic and solid tumors. Furthermore, it supports the thesis that SNAP-CAR can be a powerful technology holding the potential to be engineered to address other cancers, including HER2-expressing cancer, which COEP is targeting as its potential first-in-human clinical development program. Still, while a sure value driver, there's more to support the bullish proposition.
In April, COEP announced entering a binding term sheet with
If the transaction is finalized, it will provide Coeptis with, among other assets, exclusive rights to two FDA-approved Investigational New Drug (IND) applications and two Phase 1 clinical trials (NCT04901416, NCT04900454) investigating infusion of DVX201, an unmodified natural killer (NK) cell therapy generated from pooled donor CD34+ cells, in hematologic malignancies and viral infections. Additionally, Coeptis would gain access to a highly scalable allogeneic cellular immunotherapy platform that is being developed to generate and deliver off-the-shelf (no HLA matching), cost-effective, on-demand cell therapies to a broad patient population. Deverra expects Phase I clinical trial data from its AML study to be complete during 2H 2023.
Creating Value Through Expanding Clinical Interests
Here's more good news: According to its release, the finalized transaction would significantly expand and enhance Coeptis' technology portfolio with a cutting-edge allogeneic cell therapy platform with extensive safety and clinical data that would also enable aligning its development ambitions with leading cell and gene therapy experts. That's not all. Investors appreciate diversification, and this deal checks that box. COEP noted that adding these clinical and pre-clinical immune effector cell programs would significantly diversify its R&D capabilities and strengthen clinical pipeline assets with multiple novel approaches to combination cellular immunotherapy not yet achieved by others.
Furthermore, the inherent capabilities of the allogeneic cell therapy platform could open new pathways for Coeptis to expand its cell-based therapies beyond autologous CAR T. In fact, COEP management noted in its release that they are "excited about the possibility of exploring the application of both the SNAP-CAR and GEAR technologies to allogeneic, off-the-shelf immune effector cells. The NK and macrophage (MAC) immune effector cell generation from Deverra's platform combined with Coeptis' target specific CARs has the potential to result in development of allogeneic NK and MAC cell therapies." The excitement is warranted.
Deverra's allogeneic cell therapy platform has been used clinically since 2006, with substantial and promising clinical and safety data recorded. While that's valuable, so is the platform showing the capability to provide extreme flexibility and optionality in generating and modifying multiple distinct immune effector cell types from a single platform. Both companies believe this bringing together their established platforms could generate first-in-class allogeneic cell therapies to treat a wide range of life-threatening disorders in a cost-effective and clinically accessible way. Indeed, that's a potentially massive value driver and a near-term one at that.
There's still more intrinsic and inherent firepower contributing to the bullish thesis.
Partnerships Are Expediting Developing Much-Needed Therapeutics
Development programs with other companies put additional milestones in the crosshairs, including progress made with Deverra in evaluating an allogeneic stem cell platform and DVX201, an unmodified natural killer (NK) cell therapy in Phase 1 clinical trials, a universal, multi-antigen CAR T technology licensed from the
While the science, and especially the describing language, can be complicated, the COEP strategy isn't. Coeptis' business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements, and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer. In other words, COEP is putting in play multiple shots on goal to bring better therapeutics to market and create what could be enormous shareholder value.
Part of that can come through the exclusive option agreements with
There's another value driver. Coeptis currently has a 50% (which could scale down to 25%) revenue stream interest and co-development rights for CD38-GEAR-NK and a 50% revenue stream interest related to CD38-Diagnostic from VyGen-Bio. Coeptis is entitled to receive future revenue from both products.
Multiple Shots On Significant Rev-Gen Goals
Factoring everything in play, the most prudent way to appraise COEP is on a sum of its parts calculation. That model supports appreciably higher share prices, even well above its current level despite its massive May run. Still, that's not to say that COEP isn't worthy of significant appreciation on its parts, either. They are, with substantial intrinsic and inherent value, related to several working programs supporting that proposition. Here's the good news for COEP and its investors.
The trend lately indicates that investors are starting to recognize and seize on a window of opportunity. Understanding how the pharmaceutical sector works they are timely. In Coeptis' case, its cell and gene therapies are more than promising; they have the potential to "disrupt" current treatment paradigms. And precedent shows that larger pharma companies routinely acquire early-stage development assets in this sector.
In fact, Big Pharma like
And with analysts covering
Disclaimers:
Media Contact
Company
Contact Person:
Email: contact@primetimeprofiles.com
Phone: 917-773-0072
Country:
Website: https://primetimeprofiles.com/
.
(C) 2023 M2 COMMUNICATIONS, source